LifeArc co-founded company RQ Bio signs licensing agreement with AstraZeneca worth up to $157m plus royalties for monoclonal antibodies against SARS-CoV-2

AstraZeneca granted exclusive worldwide licence to develop, manufacture and commercialise RQ Bio’s existing early-stage monoclonal antibodies (mAbs)…

Accelerating progress against dementia 

How can we reduce the impact of dementia on individuals, families and wider society?

Learning from translational research success stories during the COVID-19 pandemic

Melanie Lee on how bringing together diverse teams united under a clear purpose can deliver extraordinary results.

Hackathon brings scientists together to tackle brain health

Together with the patient charity Motor Neurone Disease (MND) Association, LifeArc co-sponsored an MND challenge within a…

LifeArc and Scottish Government work together to drive Scottish research into rare diseases

LifeArc and the Chief Scientist Office (CSO) for the Scottish Government have today jointly awarded a total…

Covid-19 hub shortlisted for Scottish award

Unique translational research hub for Covid-19 and other viruses was a finalist in the Scottish Knowledge Exchange Awards. 

Study reveals gene faults underpinning severe COVID-19

The study paves the way for new tests and treatments to protect people from infection.

Living with genetic sight loss – a family story

Late-onset retinal degeneration (L-ORD) is a rare inherited eye disease that leads to blindness in older people.

Can an innovative gene therapy help people with Hunter syndrome?

Danny was diagnosed with Hunter syndrome when he was three years old.